It should be noted that our cohort comprised of high-risk early breast cancer patients that were all treated with chemotherapy (one of three regimens) and that, with regard to ER/PgR and HER2 status, both negative and positive patients were included in our study. This evidence concerns the gene ERBB2 and breast cancer.